Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children (NCT07142928) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children
China90 participantsStarted 2025-08-25
Plain-language summary
To evaluate the effectiveness of light-blocking lenses in promoting emmetropization and reducing anisometropia in children with hyperopic anisometropia, and to assess the impact of light-intercepting lenses on visual function in this population.
Who can participate
Age range
6 Years – 12 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 6 years or older and 12 years or younger;
* The more hyperopic eye has a spherical refractive error between +3.0 D and +7.5 D; the less hyperopic eye has a spherical refractive error of at least +2.0 D; cylindrical refractive error between -2.0 D and 0 D; interocular difference in spherical power \>=1.5 D and in cylindrical power \<=1.0 D;
* Best-corrected visual acuity of 0.0 logMAR or better in both eyes;
* Ocular deviation with spectacles less than 10 prism diopters;
* Has been wearing standard single-vision spectacles regularly for more than six months;
* In good general health, capable of receiving the study intervention, and willing to comply with the study protocol;
* Written informed consent obtained from both the parent/guardian and the child, with agreement to comply with all study procedures and maintain follow-up availability throughout the study period;
Exclusion Criteria:
* History of ocular trauma or eye surgery;
* Presence of pathological abnormalities on anterior or posterior segment examination, or a history of organic ocular diseases such as cataract, glaucoma, corneal disease, or fundus disorders;
* Intraocular pressure greater than 21 mmHg;
* Presence of systemic diseases or other conditions deemed unsuitable for study participation;
* Any other condition deemed inappropriate for participation in the clinical trial by the investigator;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Axial length
Timeframe: At baseline, 6 months, and 12 months
Trial details
NCT IDNCT07142928
SponsorZhongshan Ophthalmic Center, Sun Yat-sen University